Log in to save to my catalogue

Alzheimer's disease drug development pipeline: 2023

Alzheimer's disease drug development pipeline: 2023

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ecd89b237a8d4c8382a46b97170815de

Alzheimer's disease drug development pipeline: 2023

About this item

Full title

Alzheimer's disease drug development pipeline: 2023

Publisher

United States: John Wiley & Sons, Inc

Journal title

Alzheimer's & dementia : translational research & clinical interventions, 2023-04, Vol.9 (2), p.e12385-n/a

Language

English

Formats

Publication information

Publisher

United States: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Introduction
Drugs that prevent the onset, slow progression, or improve cognitive and behavioral symptoms of Alzheimer's disease (AD) are needed.
Methods
We searched ClinicalTrials.gov for all current Phase 1, 2 and 3 clinical trials for AD and mild cognitive impairment (MCI) attributed to AD. We created an automated computational database...

Alternative Titles

Full title

Alzheimer's disease drug development pipeline: 2023

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_ecd89b237a8d4c8382a46b97170815de

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ecd89b237a8d4c8382a46b97170815de

Other Identifiers

ISSN

2352-8737

E-ISSN

2352-8737

DOI

10.1002/trc2.12385

How to access this item